HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.

AbstractOBJECTIVES:
The aim of this study was to evaluate the impact of the phosphodiesterase (PDE) inhibitor pentoxifylline on platelet function profiles in patients receiving dual antiplatelet therapy (DAPT).
BACKGROUND:
Previous studies have shown that, in patients receiving DAPT, the adjunctive use of a PDE inhibitor enhances platelet inhibition, particularly in those presenting with diabetes mellitus (DM). However, the pharmacodynamic (PD) effects of the PDE inhibitor pentoxifylline on platelet function profiles in DM patients receiving DAPT are unknown.
METHODS:
This was a prospective, randomized, double-blind, parallel design study conducted in DM patients with stable coronary artery disease receiving DAPT. Patients were randomly assigned to either pentoxifylline 400 mg or placebo 3 times daily for 14 days. The PD effects were assessed by vasodilator-stimulated phosphoprotein phosphorylation assay, light transmittance aggregometry, VerifyNow P2Y12 assay (Accumetric, Inc., San Diego, California), and multiple electrode aggregometry at baseline and 14 days. The PD effects were also assessed according the presence or absence of high on-treatment platelet reactivity status.
RESULTS:
A total of 40 patients were available for analysis. At 14 days, there were no differences in the P2Y(12) reactivity index as assessed by vasodilator-stimulated phosphoprotein phosphorylation between treatment groups (primary endpoint; p = 0.93). Intra-group comparisons also failed to show any differences between baseline and 14-day P2Y(12) reactivity index assessment in the placebo and pentoxifylline arms (p = 0.61). There were no significant inter- and intra-group differences in all other PD measures. The PD effects did not vary according the presence or absence of high on-treatment platelet reactivity.
CONCLUSIONS:
Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT.
AuthorsMasafumi Ueno, José L Ferreiro, Salvatore D Tomasello, Antonio Tello-Montoliu, Davide Capodanno, Naveen Seecheran, Murali Kodali, Kodlipet Dharmashankar, Bhaloo Desai, Ronald K Charlton, Theodore A Bass, Dominick J Angiolillo
JournalJACC. Cardiovascular interventions (JACC Cardiovasc Interv) Vol. 4 Issue 8 Pg. 905-12 (Aug 2011) ISSN: 1876-7605 [Electronic] United States
PMID21851906 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Cell Adhesion Molecules
  • Microfilament Proteins
  • P2RY12 protein, human
  • Phosphodiesterase Inhibitors
  • Phosphoproteins
  • Platelet Aggregation Inhibitors
  • Receptors, Purinergic P2Y12
  • vasodilator-stimulated phosphoprotein
  • Clopidogrel
  • Ticlopidine
  • Aspirin
  • Pentoxifylline
Topics
  • Aged
  • Aspirin (therapeutic use)
  • Blood Platelets (drug effects, metabolism)
  • Cell Adhesion Molecules (blood)
  • Clopidogrel
  • Coronary Artery Disease (blood, drug therapy)
  • Diabetes Mellitus, Type 2 (blood)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Florida
  • Humans
  • Male
  • Microfilament Proteins (blood)
  • Middle Aged
  • Pentoxifylline (therapeutic use)
  • Phosphodiesterase Inhibitors (therapeutic use)
  • Phosphoproteins (blood)
  • Phosphorylation
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Platelet Function Tests
  • Prospective Studies
  • Receptors, Purinergic P2Y12 (drug effects, metabolism)
  • Ticlopidine (analogs & derivatives, therapeutic use)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: